Skip to application
All calculators and tools

Preparation. Administration. Evidence.

IV Dilution &
Medication Reference

Search 255 medications, read preserved historical references, and inspect separately reviewed preparation statements. Full monograph updates remain pending.

Version 6.4Release date 2026-11-04For healthcare professionals
Back to resultsA-Z list

Medication reference

Reslizumab

Monograph awaiting updateThis monograph will be updated in the future.

Jump to a section
Search DailyMed products (opens in a new tab)

Historical source. Current clinical review is incomplete. This monograph will be updated in the future.

Reslizumab- Cinqair® (opens in a new tab)Original source URL: https://globalrph.com/dilution/reslizumab-cinqair/ | Retrieved 2026-11-04

Source dates, location and integrity

This historical article is separate from the reviewed claim cards. Product formulations and source dates may differ.

Original source URL
https://globalrph.com/dilution/reslizumab-cinqair/ (opens in a new tab)
Source date
Not established in the retrieved source
Retrieved
2026-11-04T19:50:35.362783+00:00
Source location
div.post-content
Packaged content SHA-256
52cc63d01de5e013e25daaba0891ac1be01a27a5a39b12604dbe88bfbacf9f15
Original response SHA-256
06f166d3b7704c8c99ee8bf68708f61a7bba3117f46ad6dbdc717d980056d73f
Source body SHA-256
4c07cd1a9e6cd0b5c19419713b2bdb5b31277865d7c73e210b74cf4931cb6d2b

CINQAIR- reslizumab injection, solution, concentrate

[ Usual Diluents ] [ Standard Dilution ] [ Storage and Stability ]
DESCRIPTION CLINICAL PHARMACOLOGY INDICATIONS AND USAGE
CONTRAINDICATIONS PRECAUTIONS ADVERSE REACTIONS
DOSAGE AND ADMINISTRATION HOW SUPPLIED WARNINGS
PRESCRIBING HIGHLIGHTS: Please see package insert for additional information and possible updates to ensure safe and effective use of this medication. The authors make no claims of the accuracy of the information contained herein; and these suggested doses are not a substitute for clinical judgment. Neither GlobalRPh Inc. nor any other party involved in the preparation of this program shall be liable for any special, consequential, or exemplary damages resulting in whole or part from any user's use of or reliance upon this material. Please read the disclaimer carefully BEFORE accessing or using this site. BY ACCESSING OR USING THIS SITE, YOU AGREE TO BE BOUND BY THE TERMS AND CONDITIONS SET FORTH IN THE DISCLAIMER.

Drug UPDATES: [Drug information / PDF]
PACKAGE INSERT -Dosing: Click (+) next to Dosage and Administration section (drug info link)

Usual Diluents Return to article top

NS

Standard Dilutions [Amount of drug] [Infusion volume] [Infusion rate] Return to article top

[Prescribed dose - 3 mg/kg ] [50 mL] [20-50 minutes]

-If refrigerated prior to administration, allow the diluted CINQAIR solution to reach room temperature.

-Use an infusion set with an in-line, low protein-binding filter (pore size of 0.2 micron). CINQAIR is compatible with polyethersulfone (PES), polyvinylidene fluoride (PVDF), nylon, and cellulose acetate in-line infusion filters.

-Infuse the diluted solution of CINQAIR intravenously, over a 20-50 minute period. Infusion time may vary depending on the total volume to be infused as based upon patient weight.

CINQAIR is for intravenous infusion only. Do not administer as an intravenous push or bolus. The recommended dosage regimen is 3 mg/kg once every 4 weeks administered by intravenous infusion over 20-50 minutes. Discontinue the infusion immediately if the patient experiences a severe systemic reaction, including anaphylaxis.

Preparation of intravenous infusion

  1. Remove CINQAIR from the refrigerator. To minimize foaming, do not shake CINQAIR.
  2. Inspect visually for particulate matter and discoloration prior to administration. CINQAIR solution is clear to slightly hazy/opalescent, colorless to slightly yellow liquid. Since CINQAIR is a protein, proteinaceous particles may be present in the solution that appear as translucent to white, amorphous particulates. Do not administer if discolored or if other foreign particulate matter is present.
  3. Withdraw the proper volume of CINQAIR from the vial(s), based on the recommended weight-based dosage. Discard any unused portion.
  4. Dispense syringe contents slowly into an infusion bag containing 50 mL of 0.9% Sodium Chloride Injection, USP to minimize foaming of CINQAIR (CINQAIR is compatible with polyvinylchloride (PVC) or polyolefin infusion bags). Gently invert the bag to mix the solution. Do not shake. Do not mix or dilute with other drugs.
  5. Administer immediately after preparation. If not used immediately, store diluted solutions of CINQAIR in the refrigerator at 2°C to 8°C (36°F to 46°F) or at room temperature up to 25ºC (77ºF), protected from light, for up to 16 hours. The time between preparation of CINQAIR and administration should not exceed 16 hours.

Stability data:
Stability
Refrigerated		 Stability
Room Temp.		 Reconstituted
Vial/Powder		 Notes
Vials: Refrigerate at 2 ºC to 8ºC (36°F to 46°F). Do not freeze. Do not shake. Protect the vials from light by storing in the original package until time of use. Solution: Administer immediately after preparation. If not used immediately, store diluted solutions of CINQAIR in the refrigerator at 2°C to 8°C (36°F to 46°F) or at room temperature up to 25ºC (77ºF), protected from light, for up to 16 hours.

The time between preparation of CINQAIR and administration should not exceed 16 hours.

N/A

WARNINGS Return to article top

See warnings and precautions below.
WARNING:
  • WARNING: ANAPHYLAXIS

    Anaphylaxis has been observed with CINQAIR infusion in 0.3% of patients in placebo-controlled clinical studies. Anaphylaxis was reported as early as the second dose of CINQAIR [see Warnings and Precautions (5.1), Adverse Reactions (6)].

    Anaphylaxis can be life-threatening. Patients should be observed for an appropriate period of time after CINQAIR administration by a healthcare professional prepared to manage anaphylaxis. Discontinue CINQAIR immediately if the patient experiences signs or symptoms of anaphylaxis [see Dosage and Administration (2.2),Warnings and Precautions (5.1)].

DESCRIPTION Return to article top

Description:
CINQAIR® is indicated for the add-on maintenance treatment of patients with severe asthma aged 18 years and older with an eosinophilic phenotype.

Reslizumab is an interleukin-5 antagonist (IgG4, kappa). IL-5 is the major cytokine responsible for the growth and differentiation, recruitment, activation, and survival of eosinophils.

CLINICAL PHARMACOLOGY: Return to article top

Mechanism of Action:
Reslizumab is an interleukin-5 antagonist (IgG4, kappa). IL-5 is the major cytokine responsible for the growth and differentiation, recruitment, activation, and survival of eosinophils. Reslizumab binds to IL-5 with a dissociation constant of 81 pM, inhibiting the bioactivity of IL-5 by blocking its binding to the alpha chain of the IL-5 receptor complex expressed on the eosinophil surface. Inflammation is an important component in the pathogenesis of asthma. Multiple cell types (e.g., mast cells, eosinophils, neutrophils, macrophages, lymphocytes) and mediators (e.g., histamine, eicosanoids, leukotrienes, cytokines) are involved in inflammation. Reslizumab, by inhibiting IL-5 signaling, reduces the production and survival of eosinophils; however, the mechanism of reslizumab action in asthma has not been definitively established.

INDICATIONS AND USAGE Return to article top

INDICATIONS AND USAGE:
CINQAIR® is indicated for the add-on maintenance treatment of patients with severe asthma aged 18 years and older with an eosinophilic phenotype [see Clinical Studies (14)].

Limitation of Use:

•CINQAIR is not indicated for treatment of other eosinophilic conditions.
•CINQAIR is not indicated for the relief of acute bronchospasm or status asthmaticus

CONTRAINDICATIONS Return to article top

Contraindications:
Known hypersensitivity to reslizumab or any of its excipients

PRECAUTIONS Return to article top

WARNINGS AND PRECAUTIONS:

Malignancy: Malignancies were observed in clinical studies. ( 5.3)
•
Reduction in Corticosteroid Dosage: Do not discontinue systemic or inhaled corticosteroids abruptly upon initiation of therapy with CINQAIR. Decrease corticosteroids gradually, if appropriate. ( 5.4)
•
Parasitic (Helminth) Infection: Treat patients with pre-existing helminth infections before therapy with CINQAIR. If patients become infected while receiving CINQAIR and do not respond to anti-helminth treatment, discontinue CINQAIR until the parasitic infection resolves. ( 5.5)

ADVERSE REACTIONS Return to article top

ADVERSE REACTIONS:

The most common adverse reaction (incidence greater than or equal to 2%) includes oropharyngeal pain. (6.1).

To report SUSPECTED ADVERSE REACTIONS, contact Teva Pharmaceuticals at 1-888-483-8279 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.

Revised: 6/2016

See PACKAGE INSERT for PATIENT COUNSELING INFORMATION and Medication Guide.

DOSAGE AND ADMINISTRATION Return to article top

DOSAGE AND ADMINISTRATION:
•CINQAIR is for intravenous infusion only. Do not administer as an intravenous push or bolus ( 2.1)
•CINQAIR should be administered in a healthcare setting by a healthcare professional prepared to manage anaphylaxis ( 2.2)
•Recommended dosage regimen is 3 mg/kg once every 4 weeks by intravenous infusion over 20-50 minutes ( 2.1)

2.1 Dosing

CINQAIR is for intravenous infusion only. Do not administer as an intravenous push or bolus.

The recommended dosage regimen is 3 mg/kg once every 4 weeks administered by intravenous infusion over 20-50 minutes.

Discontinue the infusion immediately if the patient experiences a severe systemic reaction, including anaphylaxis [see Contraindications (4), Warnings and Precautions (5.1)].

2.2 Preparation and Administration Instructions

CINQAIR is provided as a solution in a single-use vial for intravenous infusion only and should be prepared by a healthcare professional using aseptic technique as follows:

Preparation of intravenous infusion

1.
Remove CINQAIR from the refrigerator. To minimize foaming, do not shake CINQAIR.
2.
Inspect visually for particulate matter and discoloration prior to administration. CINQAIR solution is clear to slightly hazy/opalescent, colorless to slightly yellow liquid. Since CINQAIR is a protein, proteinaceous particles may be present in the solution that appear as translucent to white, amorphous particulates. Do not administer if discolored or if other foreign particulate matter is present.
3.
Withdraw the proper volume of CINQAIR from the vial(s), based on the recommended weight-based dosage. Discard any unused portion.
4.
Dispense syringe contents slowly into an infusion bag containing 50 mL of 0.9% Sodium Chloride Injection, USP to minimize foaming of CINQAIR (CINQAIR is compatible with polyvinylchloride (PVC) or polyolefin infusion bags). Gently invert the bag to mix the solution. Do not shake. Do not mix or dilute with other drugs.
5.
Administer immediately after preparation. If not used immediately, store diluted solutions of CINQAIR in the refrigerator at 2°C to 8°C (36°F to 46°F) or at room temperature up to 25ºC (77ºF), protected from light, for up to 16 hours. The time between preparation of CINQAIR and administration should not exceed 16 hours.

Administration instructions

1.
CINQAIR should be administered in a healthcare setting by a healthcare professional prepared to manage anaphylaxis.
2.
If refrigerated prior to administration, allow the diluted CINQAIR solution to reach room temperature.
3.
Use an infusion set with an in-line, low protein-binding filter (pore size of 0.2 micron). CINQAIR is compatible with polyethersulfone (PES), polyvinylidene fluoride (PVDF), nylon, and cellulose acetate in-line infusion filters.
4.
Infuse the diluted solution of CINQAIR intravenously, over a 20-50 minute period. Infusion time may vary depending on the total volume to be infused as based upon patient weight.
5.
Do not infuse CINQAIR concomitantly in the same intravenous line with other agents. No physical or biochemical compatibility studies have been conducted to evaluate the co-administration of CINQAIR with other agents.
6.
Observe the patient over the infusion and for an appropriate period of time following infusion.
7.
Upon completion of the infusion, flush the intravenous administration set with 0.9% Sodium Chloride Injection, USP to ensure that all CINQAIR has been administered.

HOW SUPPLIED Return to article top

DOSAGE FORMS AND STRENGTHS:
CINQAIR (reslizumab) injection, 100 mg/10 mL (10 mg/mL), is supplied as a preservative-free, sterile, clear to slightly hazy/opalescent, colorless to slightly yellow solution in single-use vials. The following packaging configuration is available:

•NDC 59310-610-31: 100 mg/10 mL (10 mg/mL) single-use vial.

Storage and Stability Return to article top

Storage and Stability: Refrigerate at 2 ºC to 8ºC (36°F to 46°F). Do not freeze. Do not shake. Protect the vials from light by storing in the original package until time of use.

Open this historical article on its own

Product identifiers and clinical review status

This monograph will be updated in the future. Historical material is available where present in the original sources; full current exact-product and claim-level review remains pending.

Exact formulation, concentration, container, manufacturer, regulatory identifiers, and a reproducible label snapshot have not all been reconciled.

What remains to be completed
  • Retrievable exact-product SPL XML with version, revision, retrieval date and reproducible hash
  • Clinically reviewed, individually identified statements with two exact source mappings
  • Exact formulation, strength, container, manufacturer/labeler, application and NDC reconciliation
  • Renal-function methods and dialysis/CRRT modality review where applicable
  • Mechanism provenance, clinical source disagreements and full medication-specific safety reconciliation

Supplemental historical fields

Restored-data provenance and review notes

Source release: 2026-08-31. Current clinical review is incomplete. Original uses of current, verified, or normalized describe the historical source. They do not inherit the status of separately reviewed statements. Product formulations and source dates can differ.

Current review annotations for historical renal, dialysis, mechanism, and product fieldsSeparate renal reference: Open Renal Dosing Master (opens in a new tab)
Renal
Status
not_locally_normalized
Original classification
current_label_review_required
Entries
    General note
    Preserve the source-specific renal-function basis. An indexed CrCl table is not interchangeable with unindexed CrCl or eGFR. Generic advice to check a method does not identify the equation for a dose row.
    Dialysis
    Status
    no_local_structured_regimen
    Entries
      General note
      Named modality alone does not establish applicability. CRRT subtype, effluent rate, residual renal function, timing and interruptions require review. Historical absence is not evidence that no guidance exists.
      Mechanisms
      • Source kind
        first_look
        Local pointer
        /mechanism
        Original level
        drug_specific
        Provenance classification
        historical_drug_specific_uncorroborated
        Label derived verified
        false
        Independently corroborated
        false
        Exact label section
        Not recorded
        Original source note
        Not recorded
        Review status
        historical_unverified
        Note
        Drug-specific wording in the old file is not proof of independent corroboration or an exact label locator. Consult separately published current mechanism claims where present.
      Future update
      Status
      pending_review
      Message
      This monograph will be updated in the future as current exact-product and claim-level review is completed.
      Source unavailable
      false
      Reason
      The historical content is restored; comprehensive contemporary verification remains incomplete.
      Historical first look: uses, mechanism, dosing context, and administration

      Recovered v5.1 source content; historical, awaiting current review.

      Id
      reslizumab
      Source IDH51-220174159871FB7DAB97DFB2
      Generic name
      Reslizumab
      Source IDH51-D0D29F666DE0416D461777CE
      Class
      Biologics and immunotherapy
      Source IDH51-0D34FA026150F828FF14B283
      Subclass
      Legacy GlobalRPh directory entry
      Source IDH51-78E7F0CFF9294EA9AC2D353D
      Primary uses
      1. The current labeled immune, hematologic, neurologic, metabolic, or inflammatory indication for this targeted biologic.
        Source IDH51-FE20BF2C80BA743C59EC3003
      Mechanism
      Binds interleukin-5 and reduces eosinophil growth, activation, and survival.
      Source IDH51-1D74BBFA542B814FACC06E11
      Mechanism level
      drug_specific
      Source IDH51-AF81687C2F5FF10DF6D43C06
      Basic dosing orientation
      The existing GlobalRPh dose and preparation quick reference loads automatically below. Treat it as historical continuity, then confirm the exact current DailyMed label, population, indication, renal function, and institutional policy.
      Source IDH51-E60577D18C606DDE494D4D4E
      Administration orientation
      Route, dilution, concentration, and administration details load automatically from the existing GlobalRPh quick reference below; current exact-product verification remains required.
      Source IDH51-CB84FE4DCB0C5B2218732541
      Renal and population orientation
      Separate renal reference: Open Renal Dosing Master (opens in a new tab)Renal dosing status has not been locally normalized; use the current package insert before ordering or administration.
      Source IDH51-D07330D2C675833248F4D77A
      Key safety orientation
      1. Legacy content must be reconciled against current labeling and institutional policy before clinical use.
        Source IDH51-DBF7AE5C6322E310EDB88B4A
      Coverage path
      automatic_legacy_quick_reference
      Source IDH51-046279AFB73F2714027A93CE
      Coverage path label
      Automatic legacy GlobalRPh quick reference
      Source IDH51-D17C19556D32377D6F64F851
      Legacy title
      Reslizumab
      Source IDH51-97020C34223362434A51A6A9
      Review note
      First-look orientation only. Verify indication, patient population, weight basis, organ function, exact IV product, dose, concentration, compatibility, rate, and current labeling before use.
      Source IDH51-01F83E519773615CD945A887
      Search text
      Reslizumab Biologics and immunotherapy Legacy GlobalRPh directory entry The current labeled immune, hematologic, neurologic, metabolic, or inflammatory indication for this targeted biologic. Binds interleukin-5 and reduces eosinophil growth, activation, and survival. The existing GlobalRPh dose and preparation quick reference loads automatically below. Treat it as historical continuity, then confirm the exact current DailyMed label, population, indication, renal function, and institutional policy. Route, dilution, concentration, and administration details load automatically from the existing GlobalRPh quick reference below; current exact-product verification remains required. Renal dosing status has not been locally normalized; use the current package insert before ordering or administration. Legacy content must be reconciled against current labeling and institutional policy before clinical use. Automatic legacy GlobalRPh quick reference
      Source IDH51-8D640E510DE008AFC3CFBB5B
      Official access mode
      none
      Source IDH51-8A914CA2FF3A7DAB40FDF4C8
      Official access reason
      No source-backed DailyMed action has been verified for this umbrella or legacy record; identify the exact product before searching.
      Source IDH51-BEEC6EC15EBEE9600D288D38

      No separate structured rows were bundled for preparation, IV push, continuous infusion, population dosing, dialysis, CRRT. Historical article content and source links may cover these topics.

      Historical renal-function guidance

      Recovered v5.1 source content; historical, awaiting current review.

      Separate renal reference: Open Renal Dosing Master (opens in a new tab)
      Classification
      current_label_review_required
      Source IDH51-DDCF0F4358415ED72F96561A
      Summary
      Renal dosing status has not been locally normalized; use the current package insert before ordering or administration.
      Source IDH51-2B533228D601DC857582F951
      Method note
      Use the renal function estimate and body-size convention specified by the selected label or institutional protocol. Do not interchange Cockcroft-Gault CrCl, indexed eGFR, and de-indexed eGFR without confirming the dosing source.
      Source IDH51-CA17614AF1D07AE1909AA886

      Historical Warnings and safeguards

      Recovered v5.1 source content; historical, awaiting current review.

      1. Legacy content must be reconciled against current labeling and institutional policy before clinical use.
        Source IDH51-CCD864D2BCFDAB49C5623855

      Historical Stability notes

      Recovered v5.1 source content; historical, awaiting current review.

      1. Legacy product stability information is not automatically equivalent to a USP <797> BUD.
        Source IDH51-F8BF7D4CA35EDA564EA2BBBE
      Other recovered source fields and original editorial metadata

      Original status words such as current, verified, or normalized describe the historical source release. They do not change the clinical review status of this release.

      Catalog source fields

      Id
      reslizumab
      Source IDH51-3969BB1181A51F8D9633ADCB
      Legacy title
      Reslizumab
      Source IDH51-374DF9B028CF6E6943D8CA84
      Generic name
      Reslizumab
      Source IDH51-9093A4A136BF6641E1201C16
      Class
      Biologics and immunotherapy
      Source IDH51-303F621867145EE6DFB32AEA
      Subclass
      Legacy GlobalRPh directory entry
      Source IDH51-4CAB3041DE442B2357040A44
      Summary
      Existing GlobalRPh IV dilution monograph retained for migration into the unified reference.
      Source IDH51-6211864D0E7A35DA06B8C368
      Populations
      1. Population not yet normalized
        Source IDH51-74B85CD3A871ACDC6FC6C185
      Evidence tier
      Legacy catalog - migration review required
      Source IDH51-20F3853CDA25EDCF82D19ABC
      High alert
      false
      Source IDH51-7CDC452B2399F5B7E82BB39A
      Hazardous
      false
      Source IDH51-14858F3791FA3C9844907F3E
      Status
      Legacy migration
      Source IDH51-0609AA2149456DF034B73ABA
      Version added
      Legacy
      Source IDH51-7F9FFB09ECDA90AFC10B353C
      Sources
      LabelUrlKind
      Source IDH51-9C491A7EAADF036C406E0690
      GlobalRPh legacy IV dilution monograph
      Source IDH51-3B4BA6F733DA7D708E1B1A30
      		legacy:auto
      Source IDH51-708A7CB755B33E94E7240FBF
      		Legacy
      Source IDH51-4F628371FF2068C0C70A25A5
      Clinical release verification
      Audit version
      3.4
      Source IDH51-1ABBF6B15AAE0F7ACB82D80E
      Audited on
      2026-08-30
      Source IDH51-CDEF8BF76E9B4D4828E90906
      Level
      red
      Source IDH51-BEEF44B5B0533D4FDA80AB49
      Release gate
      unverified_or_unclassified_sources_do_not_release_as_current
      Source IDH51-4190444E9462290FC79571AC
      Exact current label candidate
      false
      Source IDH51-C0390A44FDF5EAF0DF0DD47B
      Reference url count
      0
      Source IDH51-2FDE5F50790DD659E8CD483F
      Broken reference count
      0
      Source IDH51-69513DFC9CC5DC44DC24219A
      Point of use confirmation required
      true
      Source IDH51-A0C2B87BE4EE8F4900E6A26C
      Note
      Do not treat this record as a fully current product-specific monograph until the exact IV formulation and current sources are confirmed.
      Source IDH51-F6B994A74D1C470F89732A06

      Dosing source fields

      Id
      reslizumab
      Source IDH51-A79E0573F66712016E16F45E
      Generic name
      Reslizumab
      Source IDH51-1032D95BC11142674B137467
      Coverage status
      direct_official_label_access_plus_legacy_reference
      Source IDH51-E82361674548CF13F3DB5FBA
      Package insert
      Query name
      Reslizumab
      Source IDH51-B9B5C9814521654742836F72
      Product and route must match
      true
      Source IDH51-53FE2E6B05AB28A48BD0EA62
      Live current label enabled
      false
      Source IDH51-61A36B4526ABA0C9DCFE8906
      Source priority
      Reviewed local summary when available, then a verified DailyMed label or product search when available, followed by professional references and institutional policy.
      Source IDH51-418E80984349559265F39224
      Direct official label access enabled
      true
      Source IDH51-248652F1B16243AD098A9D40
      Outbound server request required
      false
      Source IDH51-4B41247FF32993DAEB7A794F
      Local summary status
      not_bundled
      Source IDH51-D27D587F1DA5F77A6D7B45D3
      Clinical review
      Locally normalized
      false
      Source IDH51-0669061B7E1E6A1BC34124C3
      Reviewed
      2026-08-29
      Source IDH51-31C98157C34BEB5936FA086B
      Status
      Direct official package-insert access enabled; indication-specific local normalization pending.
      Source IDH51-E5947C7BBA0BD17E23A884D4
      Clinical release verification
      Audit version
      3.4
      Source IDH51-7E08C001691B9B4CAC864A89
      Audited on
      2026-08-30
      Source IDH51-61396932EE1677999167312C
      Level
      red
      Source IDH51-15DB0BA222E65879DCA9CD5D
      Release gate
      unverified_or_unclassified_sources_do_not_release_as_current
      Source IDH51-66F98B0147680E283AC24366
      Exact current label candidate
      false
      Source IDH51-79603E38D5CF54585D42151D
      Reference url count
      0
      Source IDH51-6D09B2189BD32B21C24D0FFE
      Broken reference count
      0
      Source IDH51-B8C1A9480DF1CA8772577EBA
      Point of use confirmation required
      true
      Source IDH51-24D2C527BB866954C61E24D3
      Note
      Do not treat this record as a fully current product-specific monograph until the exact IV formulation and current sources are confirmed.
      Source IDH51-68A42BF42293F00B0FFCD2A3
      Historical preparation assessment

      Recovered v5.1 source content; historical, awaiting current review.

      Id
      reslizumab
      Source IDH51-7EBBCCB556F3C6755848C6D6
      Name
      Reslizumab
      Source IDH51-A1211BC44C5E4DFF5A106BAF
      Therapeutic class
      Biologics and immunotherapy
      Source IDH51-2785B21830DC8241D6826985
      Review version
      3.1
      Source IDH51-466331C0068261A46F355E40
      Review date
      2026-08-30
      Source IDH51-44D290870D030415EF14194A
      Release status
      no_released_dilution_current_label_review_required
      Source IDH51-C450DC74CC0B740A7A5E4F1A
      Market status
      Status
      no_current_us_iv_spl_confirmed
      Source IDH51-5994AA9AD3621E9CF030F476
      Basis
      No high-confidence current IV SPL was automatically selected; legacy information is segregated
      Source IDH51-EACA269F5BCE2D8B941BA3F7
      Ten point assessment
      Exact formulation
      Not established in the currently normalized record. Use the current-label panel before clinical use.
      Source IDH51-3E58D5285C1EBC1BB27FBBD3
      Reconstitution concentration
      Not established in the currently normalized record. Use the current-label panel before clinical use.
      Source IDH51-C3F45611873E29FEEF45C751
      Maximum or recommended final concentration
      Not established in the currently normalized record. Use the current-label panel before clinical use.
      Source IDH51-EC24C5A9F18A60FDB83E0EB7
      Appropriate standardized containers
      Not established in the currently normalized record. Use the current-label panel before clinical use.
      Source IDH51-61F3021F80877D63B590DCB1
      Adult dosing range
      Not established in the currently normalized record. Use the current-label panel before clinical use.
      Source IDH51-F25B3CB78B53E23836468470
      Pediatric dosing range
      Not established in the currently normalized record. Use the current-label panel before clinical use.
      Source IDH51-B1AED328AAFCBD83BE7659C2
      Neonatal dosing range
      Not established in the currently normalized record. Use the current-label panel before clinical use.
      Source IDH51-10F1459140C924E7F15BC130
      Infusion time
      Not established in the currently normalized record. Use the current-label panel before clinical use.
      Source IDH51-7488A38E92824A26CCC6BA45
      Fluid restriction alternatives
      Not established in the currently normalized record. Use the current-label panel before clinical use.
      Source IDH51-E303F778D40CC65A5876D896
      Current manufacturer labeling
      Match confidence
      unresolved
      Source IDH51-6920637135F2294BFC2FB3B4
      Field provenance
      Exact formulation
      Primary
      not_found
      Source IDH51-4CA367AD8FF2BD1F395BF6DE
      Reconstitution concentration
      Primary
      not_found
      Source IDH51-BB35D52C174BBAEBC9AFB6F5
      Maximum or recommended final concentration
      Primary
      not_found
      Source IDH51-0268DFB89CB0490A3DE4237B
      Appropriate standardized containers
      Primary
      not_found
      Source IDH51-11C256CD12F58895549894A6
      Adult dosing range
      Primary
      not_found
      Source IDH51-55BC13379D0CA00ABA72B81B
      Pediatric dosing range
      Primary
      not_found
      Source IDH51-EF6974028F90D8D14A8D2780
      Neonatal dosing range
      Primary
      not_found
      Source IDH51-D391958FAA9B3F197C42479C
      Infusion time
      Primary
      not_found
      Source IDH51-AF6CDB3B2DEEE69CB6FECAB9
      Fluid restriction alternatives
      Primary
      not_found
      Source IDH51-A1C2E25049BA13D99145F955
      Current manufacturer labeling
      Primary
      DailyMed search gateway
      Source IDH51-6CCFC9A5A0ADFF3D92032D13
      Population applicability
      Adult
      Applicability
      not_established
      Source IDH51-5B050B3574AEBAE90037866F
      Guide generation allowed
      false
      Source IDH51-46E626DC734B75B0939F16D1
      Pediatric
      Applicability
      not_established
      Source IDH51-0DCCC5B4BD787224D7520D52
      Guide generation allowed
      false
      Source IDH51-EA8FCEA0614A967AA6DE60B3
      Neonatal
      Applicability
      not_established
      Source IDH51-91EB5AF1DB8EC6B6C97ECB01
      Guide generation allowed
      false
      Source IDH51-38C23706678FF23FED6CBDA3
      Route presence
      Structured dilution
      false
      Source IDH51-17B9D362289A7BB8EA6CC0E2
      Iv push
      false
      Source IDH51-47DED7525ED8E8EA7FC59173
      Continuous infusion
      false
      Source IDH51-12C814FCAEB6E3429F2F38C8
      Pediatric source
      false
      Source IDH51-3FB4920B8D7CAC6614398336
      Neonatal source
      false
      Source IDH51-CF479B2B91A4CC73A87C2897
      Legacy reference
      Status
      not_available
      Source IDH51-7F87DA009B25B54BF43040C7
      Label resolution
      Status
      build_environment_network_unavailable
      Source IDH51-9A541E1349DBB10C009DD464
      Source files
      1. catalog.json
        Source IDH51-116BA3C16E8FE2E422CFE80E
      2. dosing.json
        Source IDH51-17C8A2C0E6395B911C251810
      3. legacy-map.json
        Source IDH51-7F70C0E28E2C153E7E62D3E4
      4. review-queue.json
        Source IDH51-24AB20001CCC8D8EAF83F381
      Clinical release note
      Preparation instructions are released only at the evidence level shown. Legacy content remains visibly separate. Exact product, NDC, route, current labeling, and institutional policy must be confirmed.
      Source IDH51-0FBAB81466E893E0E5781464
      Historical statement IDs and source locations

      These IDs identify recovered source units. They are not evidence-qualified clinical claims.

      Historical IDOriginal source locationStatus
      H51-3969BB1181A51F8D9633ADCBcatalog.json
      /records/218/id      		Historical; current review incomplete
      H51-374DF9B028CF6E6943D8CA84catalog.json
      /records/218/legacy_title      		Historical; current review incomplete
      H51-9093A4A136BF6641E1201C16catalog.json
      /records/218/generic_name      		Historical; current review incomplete
      H51-303F621867145EE6DFB32AEAcatalog.json
      /records/218/class      		Historical; current review incomplete
      H51-4CAB3041DE442B2357040A44catalog.json
      /records/218/subclass      		Historical; current review incomplete
      H51-6211864D0E7A35DA06B8C368catalog.json
      /records/218/summary      		Historical; current review incomplete
      H51-CCD864D2BCFDAB49C5623855catalog.json
      /records/218/warnings/0      		Historical; current review incomplete
      H51-F8BF7D4CA35EDA564EA2BBBEcatalog.json
      /records/218/stability_notes/0      		Historical; current review incomplete
      H51-74B85CD3A871ACDC6FC6C185catalog.json
      /records/218/populations/0      		Historical; current review incomplete
      H51-20F3853CDA25EDCF82D19ABCcatalog.json
      /records/218/evidence_tier      		Historical; current review incomplete
      H51-7CDC452B2399F5B7E82BB39Acatalog.json
      /records/218/high_alert      		Historical; current review incomplete
      H51-14858F3791FA3C9844907F3Ecatalog.json
      /records/218/hazardous      		Historical; current review incomplete
      H51-0609AA2149456DF034B73ABAcatalog.json
      /records/218/status      		Historical; current review incomplete
      H51-0D4E4D846569C2D762D6F215catalog.json
      /records/218/reviewed      		Historical; current review incomplete
      H51-7F9FFB09ECDA90AFC10B353Ccatalog.json
      /records/218/version_added      		Historical; current review incomplete
      H51-9C491A7EAADF036C406E0690catalog.json
      /records/218/sources/0      		Historical; current review incomplete
      H51-3B4BA6F733DA7D708E1B1A30catalog.json
      /records/218/sources/0/label      		Historical; current review incomplete
      H51-708A7CB755B33E94E7240FBFcatalog.json
      /records/218/sources/0/url      		Historical; current review incomplete
      H51-4F628371FF2068C0C70A25A5catalog.json
      /records/218/sources/0/kind      		Historical; current review incomplete
      H51-1ABBF6B15AAE0F7ACB82D80Ecatalog.json
      /records/218/clinical_release_verification/audit_version      		Historical; current review incomplete
      H51-CDEF8BF76E9B4D4828E90906catalog.json
      /records/218/clinical_release_verification/audited_on      		Historical; current review incomplete
      H51-BEEF44B5B0533D4FDA80AB49catalog.json
      /records/218/clinical_release_verification/level      		Historical; current review incomplete
      H51-4190444E9462290FC79571ACcatalog.json
      /records/218/clinical_release_verification/release_gate      		Historical; current review incomplete
      H51-C0390A44FDF5EAF0DF0DD47Bcatalog.json
      /records/218/clinical_release_verification/exact_current_label_candidate      		Historical; current review incomplete
      H51-47AF397CD601CB60DEF0B515catalog.json
      /records/218/clinical_release_verification/selected_setid      		Historical; current review incomplete
      H51-A1BFEFFD0918FF7141B82243catalog.json
      /records/218/clinical_release_verification/selected_label_title      		Historical; current review incomplete
      H51-4BD01A33A82DFCDACC6A0D8Fcatalog.json
      /records/218/clinical_release_verification/numeric_support_ratio      		Historical; current review incomplete
      H51-2FDE5F50790DD659E8CD483Fcatalog.json
      /records/218/clinical_release_verification/reference_url_count      		Historical; current review incomplete
      H51-69513DFC9CC5DC44DC24219Acatalog.json
      /records/218/clinical_release_verification/broken_reference_count      		Historical; current review incomplete
      H51-A0C2B87BE4EE8F4900E6A26Ccatalog.json
      /records/218/clinical_release_verification/point_of_use_confirmation_required      		Historical; current review incomplete
      H51-F6B994A74D1C470F89732A06catalog.json
      /records/218/clinical_release_verification/note      		Historical; current review incomplete
      H51-AF21A9EE929F9A74C70B0BDDcatalog.json
      /records/218/clinical_release_verification/dailymed_search_url      		Historical; current review incomplete
      H51-A79E0573F66712016E16F45Edosing.json
      /records/218/id      		Historical; current review incomplete
      H51-1032D95BC11142674B137467dosing.json
      /records/218/generic_name      		Historical; current review incomplete
      H51-E82361674548CF13F3DB5FBAdosing.json
      /records/218/coverage_status      		Historical; current review incomplete
      H51-B9B5C9814521654742836F72dosing.json
      /records/218/package_insert/query_name      		Historical; current review incomplete
      H51-DA00782F8C880AF6108391FEdosing.json
      /records/218/package_insert/preferred_setid      		Historical; current review incomplete
      H51-53FE2E6B05AB28A48BD0EA62dosing.json
      /records/218/package_insert/product_and_route_must_match      		Historical; current review incomplete
      H51-61A36B4526ABA0C9DCFE8906dosing.json
      /records/218/package_insert/live_current_label_enabled      		Historical; current review incomplete
      H51-418E80984349559265F39224dosing.json
      /records/218/package_insert/source_priority      		Historical; current review incomplete
      H51-248652F1B16243AD098A9D40dosing.json
      /records/218/package_insert/direct_official_label_access_enabled      		Historical; current review incomplete
      H51-4B41247FF32993DAEB7A794Fdosing.json
      /records/218/package_insert/outbound_server_request_required      		Historical; current review incomplete
      H51-D27D587F1DA5F77A6D7B45D3dosing.json
      /records/218/package_insert/local_summary_status      		Historical; current review incomplete
      H51-DDCF0F4358415ED72F96561Adosing.json
      /records/218/renal/classification      		Historical; current review incomplete
      H51-2B533228D601DC857582F951dosing.json
      /records/218/renal/summary      		Historical; current review incomplete
      H51-CA17614AF1D07AE1909AA886dosing.json
      /records/218/renal/method_note      		Historical; current review incomplete
      H51-0669061B7E1E6A1BC34124C3dosing.json
      /records/218/clinical_review/locally_normalized      		Historical; current review incomplete
      H51-31C98157C34BEB5936FA086Bdosing.json
      /records/218/clinical_review/reviewed      		Historical; current review incomplete
      H51-E5947C7BBA0BD17E23A884D4dosing.json
      /records/218/clinical_review/status      		Historical; current review incomplete
      H51-7E08C001691B9B4CAC864A89dosing.json
      /records/218/clinical_release_verification/audit_version      		Historical; current review incomplete
      H51-61396932EE1677999167312Cdosing.json
      /records/218/clinical_release_verification/audited_on      		Historical; current review incomplete
      H51-15DB0BA222E65879DCA9CD5Ddosing.json
      /records/218/clinical_release_verification/level      		Historical; current review incomplete
      H51-66F98B0147680E283AC24366dosing.json
      /records/218/clinical_release_verification/release_gate      		Historical; current review incomplete
      H51-79603E38D5CF54585D42151Ddosing.json
      /records/218/clinical_release_verification/exact_current_label_candidate      		Historical; current review incomplete
      H51-3ADF8E11A5CBAA9C64C8951Ddosing.json
      /records/218/clinical_release_verification/selected_setid      		Historical; current review incomplete
      H51-804780341F398FEC67E24897dosing.json
      /records/218/clinical_release_verification/selected_label_title      		Historical; current review incomplete
      H51-0B333CD7FEF8090F0109FB71dosing.json
      /records/218/clinical_release_verification/numeric_support_ratio      		Historical; current review incomplete
      H51-6D09B2189BD32B21C24D0FFEdosing.json
      /records/218/clinical_release_verification/reference_url_count      		Historical; current review incomplete
      H51-B8C1A9480DF1CA8772577EBAdosing.json
      /records/218/clinical_release_verification/broken_reference_count      		Historical; current review incomplete
      H51-24D2C527BB866954C61E24D3dosing.json
      /records/218/clinical_release_verification/point_of_use_confirmation_required      		Historical; current review incomplete
      H51-68A42BF42293F00B0FFCD2A3dosing.json
      /records/218/clinical_release_verification/note      		Historical; current review incomplete
      H51-752EFD8F36D6D871DC25C7FAdosing.json
      /records/218/clinical_release_verification/dailymed_search_url      		Historical; current review incomplete
      H51-220174159871FB7DAB97DFB2first-look-v5.1.json
      /records/218/id      		Historical; current review incomplete
      H51-D0D29F666DE0416D461777CEfirst-look-v5.1.json
      /records/218/generic_name      		Historical; current review incomplete
      H51-0D34FA026150F828FF14B283first-look-v5.1.json
      /records/218/class      		Historical; current review incomplete
      H51-78E7F0CFF9294EA9AC2D353Dfirst-look-v5.1.json
      /records/218/subclass      		Historical; current review incomplete
      H51-FE20BF2C80BA743C59EC3003first-look-v5.1.json
      /records/218/primary_uses/0      		Historical; current review incomplete
      H51-1D74BBFA542B814FACC06E11first-look-v5.1.json
      /records/218/mechanism      		Historical; current review incomplete
      H51-AF81687C2F5FF10DF6D43C06first-look-v5.1.json
      /records/218/mechanism_level      		Historical; current review incomplete
      H51-E60577D18C606DDE494D4D4Efirst-look-v5.1.json
      /records/218/basic_dosing_orientation      		Historical; current review incomplete
      H51-CB84FE4DCB0C5B2218732541first-look-v5.1.json
      /records/218/administration_orientation      		Historical; current review incomplete
      H51-D07330D2C675833248F4D77Afirst-look-v5.1.json
      /records/218/renal_and_population_orientation      		Historical; current review incomplete
      H51-DBF7AE5C6322E310EDB88B4Afirst-look-v5.1.json
      /records/218/key_safety_orientation/0      		Historical; current review incomplete
      H51-046279AFB73F2714027A93CEfirst-look-v5.1.json
      /records/218/coverage_path      		Historical; current review incomplete
      H51-D17C19556D32377D6F64F851first-look-v5.1.json
      /records/218/coverage_path_label      		Historical; current review incomplete
      H51-921A42BCB655B5DA53EBE0F1first-look-v5.1.json
      /records/218/official_label_url      		Historical; current review incomplete
      H51-97020C34223362434A51A6A9first-look-v5.1.json
      /records/218/legacy_title      		Historical; current review incomplete
      H51-01F83E519773615CD945A887first-look-v5.1.json
      /records/218/review_note      		Historical; current review incomplete
      H51-8D640E510DE008AFC3CFBB5Bfirst-look-v5.1.json
      /records/218/search_text      		Historical; current review incomplete
      H51-B82CAD77585C0A0A4E0D5CA0first-look-v5.1.json
      /records/218/official_search_url      		Historical; current review incomplete
      H51-8A914CA2FF3A7DAB40FDF4C8first-look-v5.1.json
      /records/218/official_access_mode      		Historical; current review incomplete
      H51-95C4E6800612EC4A19610859first-look-v5.1.json
      /records/218/official_access_url      		Historical; current review incomplete
      H51-7EC5199620C47F980FCFC4BEfirst-look-v5.1.json
      /records/218/official_search_query      		Historical; current review incomplete
      H51-BEEC6EC15EBEE9600D288D38first-look-v5.1.json
      /records/218/official_access_reason      		Historical; current review incomplete
      H51-7EBBCCB556F3C6755848C6D6preparation-assessments-v3.8.json
      /218/id      		Historical; current review incomplete
      H51-A1211BC44C5E4DFF5A106BAFpreparation-assessments-v3.8.json
      /218/name      		Historical; current review incomplete
      H51-BD577DD4ABF2BFF473FD025Epreparation-assessments-v3.8.json
      /218/brands      		Historical; current review incomplete
      H51-2785B21830DC8241D6826985preparation-assessments-v3.8.json
      /218/therapeutic_class      		Historical; current review incomplete
      H51-466331C0068261A46F355E40preparation-assessments-v3.8.json
      /218/review_version      		Historical; current review incomplete
      H51-44D290870D030415EF14194Apreparation-assessments-v3.8.json
      /218/review_date      		Historical; current review incomplete
      H51-C450DC74CC0B740A7A5E4F1Apreparation-assessments-v3.8.json
      /218/release_status      		Historical; current review incomplete
      H51-5994AA9AD3621E9CF030F476preparation-assessments-v3.8.json
      /218/market_status/status      		Historical; current review incomplete
      H51-EACA269F5BCE2D8B941BA3F7preparation-assessments-v3.8.json
      /218/market_status/basis      		Historical; current review incomplete
      H51-3E58D5285C1EBC1BB27FBBD3preparation-assessments-v3.8.json
      /218/ten_point_assessment/exact_formulation      		Historical; current review incomplete
      H51-C3F45611873E29FEEF45C751preparation-assessments-v3.8.json
      /218/ten_point_assessment/reconstitution_concentration      		Historical; current review incomplete
      H51-EC24C5A9F18A60FDB83E0EB7preparation-assessments-v3.8.json
      /218/ten_point_assessment/maximum_or_recommended_final_concentration      		Historical; current review incomplete
      H51-61F3021F80877D63B590DCB1preparation-assessments-v3.8.json
      /218/ten_point_assessment/appropriate_standardized_containers      		Historical; current review incomplete
      H51-F25B3CB78B53E23836468470preparation-assessments-v3.8.json
      /218/ten_point_assessment/adult_dosing_range      		Historical; current review incomplete
      H51-B1AED328AAFCBD83BE7659C2preparation-assessments-v3.8.json
      /218/ten_point_assessment/pediatric_dosing_range      		Historical; current review incomplete
      H51-10F1459140C924E7F15BC130preparation-assessments-v3.8.json
      /218/ten_point_assessment/neonatal_dosing_range      		Historical; current review incomplete
      H51-7488A38E92824A26CCC6BA45preparation-assessments-v3.8.json
      /218/ten_point_assessment/infusion_time      		Historical; current review incomplete
      H51-E303F778D40CC65A5876D896preparation-assessments-v3.8.json
      /218/ten_point_assessment/fluid_restriction_alternatives      		Historical; current review incomplete
      H51-32877073E6A2E84BC38739CEpreparation-assessments-v3.8.json
      /218/ten_point_assessment/current_manufacturer_labeling/setid      		Historical; current review incomplete
      H51-9AD978012A2E1A3A70144B6Fpreparation-assessments-v3.8.json
      /218/ten_point_assessment/current_manufacturer_labeling/title      		Historical; current review incomplete
      H51-562C338521B4B14EBD85E1ECpreparation-assessments-v3.8.json
      /218/ten_point_assessment/current_manufacturer_labeling/published_date      		Historical; current review incomplete
      H51-AC9EE9C2A4E584C326540EC0preparation-assessments-v3.8.json
      /218/ten_point_assessment/current_manufacturer_labeling/manufacturer      		Historical; current review incomplete
      H51-6920637135F2294BFC2FB3B4preparation-assessments-v3.8.json
      /218/ten_point_assessment/current_manufacturer_labeling/match_confidence      		Historical; current review incomplete
      H51-FCE55F7CC850664A7BAF7404preparation-assessments-v3.8.json
      /218/ten_point_assessment/current_manufacturer_labeling/url      		Historical; current review incomplete
      H51-4CA367AD8FF2BD1F395BF6DEpreparation-assessments-v3.8.json
      /218/field_provenance/exact_formulation/primary      		Historical; current review incomplete
      H51-BB35D52C174BBAEBC9AFB6F5preparation-assessments-v3.8.json
      /218/field_provenance/reconstitution_concentration/primary      		Historical; current review incomplete
      H51-0268DFB89CB0490A3DE4237Bpreparation-assessments-v3.8.json
      /218/field_provenance/maximum_or_recommended_final_concentration/primary      		Historical; current review incomplete
      H51-11C256CD12F58895549894A6preparation-assessments-v3.8.json
      /218/field_provenance/appropriate_standardized_containers/primary      		Historical; current review incomplete
      H51-55BC13379D0CA00ABA72B81Bpreparation-assessments-v3.8.json
      /218/field_provenance/adult_dosing_range/primary      		Historical; current review incomplete
      H51-EF6974028F90D8D14A8D2780preparation-assessments-v3.8.json
      /218/field_provenance/pediatric_dosing_range/primary      		Historical; current review incomplete
      H51-D391958FAA9B3F197C42479Cpreparation-assessments-v3.8.json
      /218/field_provenance/neonatal_dosing_range/primary      		Historical; current review incomplete
      H51-AF6CDB3B2DEEE69CB6FECAB9preparation-assessments-v3.8.json
      /218/field_provenance/infusion_time/primary      		Historical; current review incomplete
      H51-A1C2E25049BA13D99145F955preparation-assessments-v3.8.json
      /218/field_provenance/fluid_restriction_alternatives/primary      		Historical; current review incomplete
      H51-6CCFC9A5A0ADFF3D92032D13preparation-assessments-v3.8.json
      /218/field_provenance/current_manufacturer_labeling/primary      		Historical; current review incomplete
      H51-5B050B3574AEBAE90037866Fpreparation-assessments-v3.8.json
      /218/population_applicability/adult/applicability      		Historical; current review incomplete
      H51-46E626DC734B75B0939F16D1preparation-assessments-v3.8.json
      /218/population_applicability/adult/guide_generation_allowed      		Historical; current review incomplete
      H51-0DCCC5B4BD787224D7520D52preparation-assessments-v3.8.json
      /218/population_applicability/pediatric/applicability      		Historical; current review incomplete
      H51-EA8FCEA0614A967AA6DE60B3preparation-assessments-v3.8.json
      /218/population_applicability/pediatric/guide_generation_allowed      		Historical; current review incomplete
      H51-91EB5AF1DB8EC6B6C97ECB01preparation-assessments-v3.8.json
      /218/population_applicability/neonatal/applicability      		Historical; current review incomplete
      H51-38C23706678FF23FED6CBDA3preparation-assessments-v3.8.json
      /218/population_applicability/neonatal/guide_generation_allowed      		Historical; current review incomplete
      H51-17B9D362289A7BB8EA6CC0E2preparation-assessments-v3.8.json
      /218/route_presence/structured_dilution      		Historical; current review incomplete
      H51-47DED7525ED8E8EA7FC59173preparation-assessments-v3.8.json
      /218/route_presence/iv_push      		Historical; current review incomplete
      H51-12C814FCAEB6E3429F2F38C8preparation-assessments-v3.8.json
      /218/route_presence/continuous_infusion      		Historical; current review incomplete
      H51-3FB4920B8D7CAC6614398336preparation-assessments-v3.8.json
      /218/route_presence/pediatric_source      		Historical; current review incomplete
      H51-CF479B2B91A4CC73A87C2897preparation-assessments-v3.8.json
      /218/route_presence/neonatal_source      		Historical; current review incomplete
      H51-7F87DA009B25B54BF43040C7preparation-assessments-v3.8.json
      /218/legacy_reference/status      		Historical; current review incomplete
      H51-9A541E1349DBB10C009DD464preparation-assessments-v3.8.json
      /218/label_resolution/status      		Historical; current review incomplete
      H51-116BA3C16E8FE2E422CFE80Epreparation-assessments-v3.8.json
      /218/source_files/0      		Historical; current review incomplete
      H51-17C8A2C0E6395B911C251810preparation-assessments-v3.8.json
      /218/source_files/1      		Historical; current review incomplete
      H51-7F70C0E28E2C153E7E62D3E4preparation-assessments-v3.8.json
      /218/source_files/2      		Historical; current review incomplete
      H51-24AB20001CCC8D8EAF83F381preparation-assessments-v3.8.json
      /218/source_files/3      		Historical; current review incomplete
      H51-0FBAB81466E893E0E5781464preparation-assessments-v3.8.json
      /218/clinical_release_note      		Historical; current review incomplete

      Open the original GlobalRPh site monograph (historical; not revalidated) (opens in a new tab)

      All medicationsReturn to medication headingApplication top